Brief: U.S. FDA Approves First Therapeutic Indication For Revance's DAXXIFY For Injection For Treatment Of Cervical Dystonia In Adults

Revance Therapeutics

14/08/2023 13:00

Aug 14 (Reuters) - Revance Therapeutics Inc  RVNC.O :
    * REVANCE THERAPEUTICS‍​:APPROVAL EXPANDS DAXXIFY LABEL TO
INCLUDE
EFFICACY DATA OVER 52-WEEK ASPEN REPEAT DOSE CLINICAL STUDY
    * U.S. FDA APPROVES FIRST THERAPEUTIC INDICATION FOR
REVANCE’S
DAXXIFY FOR INJECTION FOR TREATMENT OF CERVICAL DYSTONIA IN
ADULTS

Further company coverage:  RVNC.O 

 ((Reuters.Briefs@thomsonreuters.com;))